Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Heimtraining der Atemmuskulatur und Aerobic-Übungsprogramme zur Verbesserung der Lungengesundheit bei aktuellen und ehemaligen Zigarettenrauchern

5. November 2026 aktualisiert von: Roswell Park Cancer Institute

Auswirkungen von Atemmuskeltraining und aerobem Training auf die Lungengesundheit bei Rauchern: Eine Pilot-Parallelgruppenstudie zur Prävention von Lungenkrebs

This clinical trial studies whether home-based respiratory muscle training (RMT) and aerobic exercise (AE) programs can be used to improve lung health in current and former cigarette smokers. Lung cancer, the leading cause of cancer death, is overwhelmingly caused by exposure to cigarette smoke. Research suggests that daily activity reduces lung cancer risk in current and former smokers. However, current and former smokers are generally not active and new approaches to improve lung health are needed. During the home-based RMT program, participants use a handheld device to complete breathing exercise sessions consisting of breathing in and out against adjustable resistance. During the home-based AE program, participants complete aerobic exercises using a stationary bike working at a moderate workload against adjustable resistance. The home-based RMT and AE programs may be effective ways to strengthen the breathing muscles, which may improve lung health in current and former cigarette smokers.

Studienübersicht

Detaillierte Beschreibung

PRIMARY OBJECTIVES:

I. Evaluate the feasibility of delivering a home-based AE and RMT program in individuals at high risk for lung cancer.

II. Assess the effects of AE and RMT on patient-reported outcomes (PROs), including QoL, fatigue, dyspnea, performance metrics such as respiratory muscle strength and lower extremity strength; the 6-minute walk test; and daily activity levels in high-risk individuals.

III. Investigate whether RMT and/or AE improve peripheral and exhaled biomarkers associated with lung injury, inflammation, and/or oxidative stress.

OUTLINE: Participants scheduled for a computed tomography (CT) scan are assigned to cohort A, participants who call the New York State Quitline (NYSQL) are assigned to cohort B.

COHORT A: Participants are randomized to 1 of 3 arms.

ARM I: Participants complete RMT sessions via the Power Lung device over 20-30 minutes each consisting of three sets of 15 breaths at a gradual increase in resistance, 5 days a week, for 12 weeks in the absence of unacceptable toxicity. Participants also receive a virtually supervised session/call once a week (QW) to provide support, enhance safety, and promote training compliance on study.

ARM II: Participants complete tailored intensity AE cycling sessions progressing to over 30 minutes each, 5 days a week, for 12 weeks in the absence of unacceptable toxicity. Participants also receive a virtually supervised session/call QW to provide support, enhance safety, and promote training compliance on study.

ARM III: Participants receive education on AE and RMT including recommendations aligned with current guidelines 5 days a week for 12 weeks.

COHORT B: Participants are randomized to 1 of 2 arms.

ARM IV: Participants complete RMT sessions as in arm I for 12 weeks in the absence of unacceptable toxicity. Participants also receive a virtually supervised session/call QW to provide support, enhance safety, and promote training compliance on study.

ARM V: Participants receive education on AE and RMT as in arm III on study.

Additionally, all patients undergo blood, nasal swab, exhaled breath, and urine sample collection on study.

After completion of study intervention, participants may be optionally followed up at week 24.

Studientyp

Interventionell

Einschreibung (Geschätzt)

200

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • New York
      • Buffalo, New York, Vereinigte Staaten, 14263
        • Roswell Park Cancer Institute
        • Kontakt:
        • Hauptermittler:
          • Andrew D. Ray

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

50 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Ja

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Age ≥ 50 years old
  • Current smoker with a ≥ 20-pack-years history
  • Former smoker within the past 15 years, with a history of ≥ 20 pack-years (CT scan cohort only)
  • Participant must be able to speak, read and comprehend English language
  • Cognitively capable of following direction and performing the intervention
  • Understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure

Exclusion Criteria:

  • Any previous lung cancer diagnoses and or undergoing treatment for any cancer
  • Recent pneumonia, bronchitis, or other inflammatory conditions in the lungs, including but limited to chronic obstructive pulmonary disease (COPD) and/or asthma exacerbation within the previous 6 months
  • Have uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, heart failure or psychiatric illness/social situations that would limit compliance with study requirements
  • Unwilling or unable to follow protocol requirements
  • Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study intervention

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Verhütung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Cohort A Arm I (RMT)

Participants complete RMT sessions via the Power Lung device over 20-30 minutes each consisting of three sets of 15 breaths at a gradual increase in resistance, 5 days a week, for 12 weeks in the absence of unacceptable toxicity. Participants also receive a virtually supervised session/call QW to provide support, enhance safety, and promote training compliance on study. Additionally, patients undergo blood, nasal swab, exhaled breath, and urine sample collection on study.

Ancillary studies

Ancillary studies

Ancillary studies

Andere Namen:
  • Testen der körperlichen Fitness
  • Körperliche Funktionsprüfung

Ancillary studies

Undergo blood, nasal swab, exhaled breath, and urine sample collection

Andere Namen:
  • Biologische Probensammlung
  • Bioprobe gesammelt
  • Probenentnahme

Complete RMT sessions

Andere Namen:
  • RMT

Receive virtually supervised session/call

Andere Namen:
  • Unterstützende Therapie
  • Symptommanagement
  • Therapie, unterstützend
Experimental: Cohort A Arm II (AE)

Participants complete tailored intensity AE cycling sessions progressing to over 30 minutes each, 5 days a week, for 12 weeks in the absence of unacceptable toxicity. Participants also receive a virtually supervised session/call QW to provide support, enhance safety, and promote training compliance on study. Additionally, patients undergo blood, nasal swab, exhaled breath, and urine sample collection on study.

Ancillary studies

Ancillary studies

Ancillary studies

Andere Namen:
  • Testen der körperlichen Fitness
  • Körperliche Funktionsprüfung

Ancillary studies

Undergo blood, nasal swab, exhaled breath, and urine sample collection

Andere Namen:
  • Biologische Probensammlung
  • Bioprobe gesammelt
  • Probenentnahme

Receive virtually supervised session/call

Andere Namen:
  • Unterstützende Therapie
  • Symptommanagement
  • Therapie, unterstützend

Complete tailored intensity AE cycling sessions

Andere Namen:
  • Aerobe Aktivität
Aktiver Komparator: Cohort A Arm III (AE and RMT education)

Participants receive education on AE and RMT including recommendations aligned with current guidelines 5 days a week for 12 weeks. Additionally, patients undergo blood, nasal swab, exhaled breath, and urine sample collection on study.

Ancillary studies

Ancillary studies

Ancillary studies

Andere Namen:
  • Testen der körperlichen Fitness
  • Körperliche Funktionsprüfung

Ancillary studies

Undergo blood, nasal swab, exhaled breath, and urine sample collection

Andere Namen:
  • Biologische Probensammlung
  • Bioprobe gesammelt
  • Probenentnahme

Receive AE and RMT education

Andere Namen:
  • Erziehung zum Eingreifen
  • Intervention durch Bildung
  • Intervention, pädagogisch
Experimental: Cohort B Arm IV (RMT)

Participants complete RMT sessions as in arm I for 12 weeks in the absence of unacceptable toxicity. Participants also receive a virtually supervised session/call QW to provide support, enhance safety, and promote training compliance on study. Additionally, patients undergo blood, nasal swab, exhaled breath, and urine sample collection on study.

Ancillary studies

Ancillary studies

Andere Namen:
  • Testen der körperlichen Fitness
  • Körperliche Funktionsprüfung

Ancillary studies

Undergo blood, nasal swab, exhaled breath, and urine sample collection

Andere Namen:
  • Biologische Probensammlung
  • Bioprobe gesammelt
  • Probenentnahme

Complete RMT sessions

Andere Namen:
  • RMT

Receive virtually supervised session/call

Andere Namen:
  • Unterstützende Therapie
  • Symptommanagement
  • Therapie, unterstützend
Aktiver Komparator: Cohort B Arm V (AE and RMT education)

Participants receive education on AE and RMT as in arm III on study. Additionally, patients undergo blood, nasal swab, exhaled breath, and urine sample collection on study.

Ancillary studies

Ancillary studies

Andere Namen:
  • Testen der körperlichen Fitness
  • Körperliche Funktionsprüfung

Ancillary studies

Undergo blood, nasal swab, exhaled breath, and urine sample collection

Andere Namen:
  • Biologische Probensammlung
  • Bioprobe gesammelt
  • Probenentnahme

Receive AE and RMT education

Andere Namen:
  • Erziehung zum Eingreifen
  • Intervention durch Bildung
  • Intervention, pädagogisch

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Compliance rate (Feasibility)
Zeitfenster: Up to 12 weeks

The primary objective is in the feasibility of conducting the respiratory muscle training (RMT) and aerobic exercise (AE) intervention relative to the sham control. In the RMT group, overall compliance (e.g., compliant at all time points) will be estimated using 90% confidence intervals (CIs) obtained Clopper-Pearson method. The lower bounds will define a plausible lower limit for true (unobserved) compliance rates. Additionally, compliance status will be modeled as a function of time (e.g., week), and pre-specified exogenous factors using a generalized estimating equation logistic regression model (autoregressive covariance structure). Estimates of compliance rates will be obtained by time-point and tests about the appropriate contrasts of model estimates will be used to determine if there is a time trend.

Up to 12 weeks
Adherence rate (Feasibility)
Zeitfenster: Up to 12 weeks

The primary objective is in the feasibility of conducting the RMT and AE intervention relative to the sham control. In the RMT group, overall adherence (complete ≥ 70% of sessions) rates will be estimated using 90% CIs obtained Clopper-Pearson method. The lower bounds will define a plausible lower limit for true (unobserved) adherence rates.

Up to 12 weeks
Assessing inspiratory and expiratory muscle strength
Zeitfenster: At baseline, 6 weeks, and 12 weeks

Participants will complete 3 sets of 15 breaths, 5 days/week using commercially available Power Lung. resistance will be increased 5-10% every week . Participants will rate and log their effort

At baseline, 6 weeks, and 12 weeks
change in St. George Respiratory Questionnaire (SGRQ)
Zeitfenster: At baseline, 6 weeks, and 12 weeks

The SGRQ comprises of 50 items and consists of two parts. Scores range from 0-100, with higher scores indicating worse quality of life.

At baseline, 6 weeks, and 12 weeks
Functional capacity
Zeitfenster: At baseline, 6 weeks, and 12 weeks

Measured by the 6-Minute Walk Test. Will be summarized at pre-, 6-week and post-intervention timepoints, regardless of treatment regimen, using the appropriate descriptive statistics and graphically summarized. The outcome will be analyzed using a linear mixed model, with the intervention arms and time points as predictors. Baseline measurements will be included as a covariate to adjust for initial differences. Both within-and between-group comparisons will be conducted using appropriate contrasts. The primary comparisons will focus on between-arm differences at the 12-week post-intervention time point. Comparisons at the 6-week and 3-month follow-up visits will be secondary and will only be performed if the primary comparison for the corresponding endpoint reaches statistical significance. For cohort A, Bonferroni's correction will be applied to adjust for three pairwise comparisons.

At baseline, 6 weeks, and 12 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Lower extremity strength
Zeitfenster: At baseline and 12 weeks

Measured using the 30-Second Sit-to-Stand Test. The outcome will be analyzed using a linear mixed model, with the intervention arms and time points as predictors. Baseline measurements will be included as a covariate to adjust for initial differences. Both within-and between-group comparisons will be conducted using appropriate contrasts. The primary comparisons will focus on between-arm differences at the 12-week post-intervention time point.

At baseline and 12 weeks
Physical performance
Zeitfenster: At baseline and 12 weeks

Measured using the Short Physical Performance Battery. The outcome will be analyzed using a linear mixed model, with the intervention arms and time points as predictors. Baseline measurements will be included as a covariate to adjust for initial differences. Both within-and between-group comparisons will be conducted using appropriate contrasts. The primary comparisons will focus on between-arm differences at the 12-week post-intervention time point.

At baseline and 12 weeks
Physical activity levels
Zeitfenster: Up to 12 weeks

daily step counts and minutes at various intensity levels will be monitored with an activity tracker. Both within-and between-group comparisons will be conducted using appropriate contrasts. The primary comparisons will focus on between-arm differences at the 12-week post-intervention time point.

Up to 12 weeks
Patient-reported outcomes on Fatigue
Zeitfenster: At baseline and 12 weeks

he Functional Assessment of Chronic Illness Therapy (FACIT- fatigue scale) is a 13-item patient-reported measure of fatigue. Items are scored on a 0 - 4 response scale with anchors ranging from "Not at all" to "Very much so". To score the FACIT-fatigue, all items are summed to create a single fatigue score with a range from 0 to 52. The higher the score, the lower the score the greater the fatigue severity

At baseline and 12 weeks
High-sensitivity C-reactive protein
Zeitfenster: At baseline and 12 weeks

The outcome will be analyzed using a linear mixed model, with the intervention arms and time points as predictors. Baseline measurements will be included as a covariate to adjust for initial differences. Both within-and between-group comparisons will be conducted using appropriate contrasts. The primary comparisons will focus on between-arm differences at the 12-week post-intervention time point.

At baseline and 12 weeks
Cardiac biomarkers
Zeitfenster: At baseline and at 12 weeks

Will assess cardiac biomarkers, such as high-sensitivity troponin T and N-terminal pro-brain natriuretic peptide. The outcome will be analyzed using a linear mixed model, with the intervention arms and time points as predictors. Baseline measurements will be included as a covariate to adjust for initial differences. Both within-and between-group comparisons will be conducted using appropriate contrasts. The primary comparisons will focus on between-arm differences at the 12-week post-intervention time point. Biomarker data will be appropriately transformed prior to analysis to meet model assumptions.

At baseline and at 12 weeks
Dyspnea patient reported response
Zeitfenster: Baseline and at 12 weeks

he Dyspnea-12 describes the different qualitative dimensions of breathlessness. Each 12- item (seven for the physical and five for the affective components) score ranges from 'none' (score 0) to 'severe' (score 3) with a total score ranging from 0 to 36 (lower is better), a physical score ranging from 0 to 21 and an affective score ranging from 0 to 15

Baseline and at 12 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Ermittler

  • Hauptermittler: Andrew D Ray, Roswell Park Cancer Institute

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

15. Dezember 2026

Primärer Abschluss (Geschätzt)

1. Mai 2029

Studienabschluss (Geschätzt)

1. Mai 2029

Studienanmeldedaten

Zuerst eingereicht

1. April 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

20. April 2026

Zuerst gepostet (Tatsächlich)

28. April 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

6. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

5. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren